Denali Therapeutics (DNLI) Research & Development: 2017-2024
Historic Research & Development for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to $99.8 million.
- Denali Therapeutics' Research & Development fell 7.44% to $99.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $396.4 million, marking a year-over-year decrease of 6.47%. This contributed to the annual value of $396.4 million for FY2024, which is 6.47% down from last year.
- Denali Therapeutics' Research & Development amounted to $99.8 million in Q4 2024, which was up 1.58% from $98.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' Research & Development ranged from a high of $128.8 million in Q1 2023 and a low of $51.0 million during Q1 2020.
- For the 3-year period, Denali Therapeutics' Research & Development averaged around $98.3 million, with its median value being $95.1 million (2022).
- Its Research & Development has fluctuated over the past 5 years, first surged by 49.62% in 2023, then decreased by 16.92% in 2024.
- Denali Therapeutics' Research & Development (Quarterly) stood at $54.7 million in 2020, then rose by 23.99% to $67.9 million in 2021, then soared by 35.70% to $92.1 million in 2022, then grew by 17.04% to $107.8 million in 2023, then fell by 7.44% to $99.8 million in 2024.
- Its Research & Development stands at $99.8 million for Q4 2024, versus $98.2 million for Q3 2024 and $91.4 million for Q2 2024.